462 related articles for article (PubMed ID: 23609382)
1. Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study.
Rezaei F; Mohammad-Karimi M; Seddighi S; Modabbernia A; Ashrafi M; Salehi B; Hammidi S; Motasami H; Hajiaghaee R; Tabrizi M; Akhondzadeh S
J Clin Psychopharmacol; 2013 Jun; 33(3):336-42. PubMed ID: 23609382
[TBL] [Abstract][Full Text] [Related]
2. Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.
Khodaie-Ardakani MR; Seddighi S; Modabbernia A; Rezaei F; Salehi B; Ashrafi M; Shams-Alizadeh N; Mohammad-Karimi M; Esfandiari GR; Hajiaghaee R; Akhondzadeh S
J Psychiatr Res; 2013 Apr; 47(4):472-8. PubMed ID: 23375406
[TBL] [Abstract][Full Text] [Related]
3. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
[TBL] [Abstract][Full Text] [Related]
4. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.
Hosseini SM; Farokhnia M; Rezaei F; Gougol A; Yekehtaz H; Iranpour N; Salehi B; Tabrizi M; Tajdini M; Ghaleiha A; Akhondzadeh S
Eur Neuropsychopharmacol; 2014 Jun; 24(6):846-55. PubMed ID: 24636461
[TBL] [Abstract][Full Text] [Related]
5. A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia.
Lieberman JA; Papadakis K; Csernansky J; Litman R; Volavka J; Jia XD; Gage A;
Neuropsychopharmacology; 2009 Apr; 34(5):1322-9. PubMed ID: 19005465
[TBL] [Abstract][Full Text] [Related]
6. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.
Modabbernia A; Rezaei F; Salehi B; Jafarinia M; Ashrafi M; Tabrizi M; Hosseini SM; Tajdini M; Ghaleiha A; Akhondzadeh S
CNS Drugs; 2013 Jan; 27(1):57-65. PubMed ID: 23233269
[TBL] [Abstract][Full Text] [Related]
7. N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study.
Farokhnia M; Azarkolah A; Adinehfar F; Khodaie-Ardakani MR; Hosseini SM; Yekehtaz H; Tabrizi M; Rezaei F; Salehi B; Sadeghi SM; Moghadam M; Gharibi F; Mirshafiee O; Akhondzadeh S
Clin Neuropharmacol; 2013; 36(6):185-92. PubMed ID: 24201233
[TBL] [Abstract][Full Text] [Related]
8. Citicoline (CDP-choline) add-on therapy to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial.
Ghajar A; Gholamian F; Tabatabei-Motlagh M; Afarideh M; Rezaei F; Ghazizadeh-Hashemi M; Akhondzadeh S
Hum Psychopharmacol; 2018 Jul; 33(4):e2662. PubMed ID: 29901250
[TBL] [Abstract][Full Text] [Related]
9. Effects of warm-supplementing kidney yang (WSKY) capsule added on risperidone on cognition in chronic schizophrenic patients: a randomized, double-blind, placebo-controlled, multi-center clinical trial.
Chen ZH; Wang GH; Wang XP; Chen RY; Wang HL; Yang MH; Huo YX; Mei HB
Hum Psychopharmacol; 2008 Aug; 23(6):465-70. PubMed ID: 18536066
[TBL] [Abstract][Full Text] [Related]
10. A Placebo-Controlled Study of Raloxifene Added to Risperidone in Men with Chronic Schizophrenia.
Khodaie-Ardakani MR; Khosravi M; Zarinfard R; Nejati S; Mohsenian A; Tabrizi M; Akhondzadeh S
Acta Med Iran; 2015; 53(6):337-45. PubMed ID: 26069170
[TBL] [Abstract][Full Text] [Related]
11. An open-label, randomized, controlled trial of zotepine and risperidone for acutely ill, hospitalized, schizophrenic patients with symptoms of agitation.
Chan HY; Lin AS; Chen KP; Cheng JS; Chen YY; Tsai CJ
J Clin Psychopharmacol; 2013 Dec; 33(6):747-52. PubMed ID: 24100785
[TBL] [Abstract][Full Text] [Related]
12. Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.
Khodaie-Ardakani MR; Mirshafiee O; Farokhnia M; Tajdini M; Hosseini SM; Modabbernia A; Rezaei F; Salehi B; Yekehtaz H; Ashrafi M; Tabrizi M; Akhondzadeh S
Psychiatry Res; 2014 Mar; 215(3):540-6. PubMed ID: 24480077
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
[TBL] [Abstract][Full Text] [Related]
15. A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia.
Salimi S; Fotouhi A; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Mohammadi MR; Noorbala AA; Ahmadi-Abhari SA; Hajiazim M; Abbasi SH; Akhondzadeh S
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):726-32. PubMed ID: 18096287
[TBL] [Abstract][Full Text] [Related]
16. The effects of add-on low-dose memantine on cytokine levels in bipolar II depression: a 12-week double-blind, randomized controlled trial.
Lee SY; Chen SL; Chang YH; Chen PS; Huang SY; Tzeng NS; Wang YS; Wang LJ; Lee IH; Wang TY; Yeh TL; Yang YK; Hong JS; Lu RB
J Clin Psychopharmacol; 2014 Jun; 34(3):337-43. PubMed ID: 24717258
[TBL] [Abstract][Full Text] [Related]
17. Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia.
Schaefer M; Sarkar S; Theophil I; Leopold K; Heinz A; Gallinat J
Pharmacopsychiatry; 2020 Jan; 53(1):21-29. PubMed ID: 31390660
[TBL] [Abstract][Full Text] [Related]
18. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
Amiri A; Noorbala AA; Nejatisafa AA; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Hajiazim M; Raznahan M; Akhondzadeh S
Hum Psychopharmacol; 2008 Mar; 23(2):79-86. PubMed ID: 17972359
[TBL] [Abstract][Full Text] [Related]
20. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic.
Kane JM; Eerdekens M; Lindenmayer JP; Keith SJ; Lesem M; Karcher K
Am J Psychiatry; 2003 Jun; 160(6):1125-32. PubMed ID: 12777271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
